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ABSTRACT
Background Immunotherapy with checkpoint inhibitors 
has shown impressive results in patients with melanoma, 
but still many do not benefit from this line of treatment. A 
lack of tumor- infiltrating T cells is a common reason for 
therapy failure but also a loss of intratumoral dendritic 
cells (DCs) has been described.
Methods We used the transgenic tg(Grm1)EPv melanoma 
mouse strain that develops spontaneous, slow- growing 
tumors to perform immunological analysis during tumor 
progression. With flow cytometry, the frequencies of DCs 
and T cells at different tumor stages and the expression of 
the inhibitory molecules programmed cell death protein-1 
(PD-1) and T- cell immunoglobulin and mucin- domain 
containing-3 (TIM-3) on T cells were analyzed. This was 
complemented with RNA- sequencing (RNA- seq) and real- 
time quantitative PCR (RT- qPCR) analysis to investigate the 
immune status of the tumors. To boost DC numbers and 
function, we administered Fms- related tyrosine 3 ligand 
(Flt3L) plus an adjuvant mix of polyI:C and anti- CD40. To 
enhance T cell function, we tested several checkpoint 
blockade antibodies. Immunological alterations were 
characterized in tumor and tumor- draining lymph nodes 
(LNs) by flow cytometry, CyTOF, microarray and RT- qPCR to 
understand how immune cells can control tumor growth. 
The specific role of migratory skin DCs was investigated 
by coculture of sorted DC subsets with melanoma- specific 
CD8+ T cells.
Results Our study revealed that tumor progression is 
characterized by upregulation of checkpoint molecules 
and a gradual loss of the dermal conventional DC (cDC) 2 
subset. Monotherapy with checkpoint blockade could not 
restore antitumor immunity, whereas boosting DC numbers 
and activation increased tumor immunogenicity. This was 
reflected by higher numbers of activated cDC1 and cDC2 
as well as CD4+ and CD8+ T cells in treated tumors. At the 
same time, the DC boost approach reinforced migratory 
dermal DC subsets to prime gp100- specific CD8+ T 
cells in tumor- draining LNs that expressed PD-1/TIM-3 
and produced interferon γ (IFNγ)/tumor necrosis factor 
α (TNFα). As a consequence, the combination of the DC 
boost with antibodies against PD-1 and TIM-3 released the 
brake from T cells, leading to improved function within the 
tumors and delayed tumor growth.
Conclusions Our results set forth the importance of 
skin DC in cancer immunotherapy, and demonstrates 
that restoring DC function is key to enhancing tumor 
immunogenicity and subsequently responsiveness to 
checkpoint blockade therapy.
BACKGROUND
Invasive melanoma is the most fatal type 
of skin cancer.1 Although treatment with 
immune checkpoint inhibitors improves clin-
ical outcome for patients with melanoma, 
there is still a large portion of patients that do 
not respond to this line of therapy.2 3 Resis-
tance to checkpoint blockade therapy has 
been associated with decreased numbers 
of tumor- infiltrating effector T cells and 
increased numbers of immunosuppressive 
cells such as myeloid- derived suppressor cells 
(MDSCs) and regulatory CD4+ T cells (CD4+ 
Tregs). Moreover, infiltrating T cells are often 
impaired in their function.4
A recent study highlighted the impor-
tance of dendritic cell (DC)–T cell crosstalk 
during checkpoint blockade therapy.5 DCs 
are the most important antigen presenting 
cells for the induction of antitumor immune 
responses as they are equipped with the 
unique ability to cross- present exogenously 
derived antigen.6–9 It has been reported that 
DCs in patients with melanoma are decreased 
in their numbers, a fact that has been asso-
ciated with a worse prognosis.10 DC numbers 
are normally kept under control by mani-
fold mechanisms that mediate their survival 
and/or apoptosis.11 The various DC subsets 
in tissues are dependent on growth factors 
and cytokines. Langerhans cells (LCs), the 
only DC subset present in the epidermis, are 
very long lived cells and their homeostasis is 
dependent on transforming growth factor-β 
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(TGF-β).12 13 Within the murine dermis, there are various 
DC subsets that can be distinguished on the basis of 
langerin, CD11b and CD103 expression; their survival is 
dependent on Flt3L.14 15 It has been reported that Flt3L 
can enrich all the conventional DC populations in various 
tissues except for LCs.16–18 Indeed, a recent study using 
melanoma mouse models has shown that treatment with 
Flt3L can increase intratumoral CD103+ cDC1 and that 
this subset has the most potent cross- presenting capacity 
in the tumor.7
The high percentage of patients with melanoma that 
do not respond to checkpoint blockade illustrates the 
need to develop combination approaches. For therapy 
development, preclinical studies that use mouse models 
that mimic human disease can be highly advantageous. 
In this study, we used the transgenic tg(Grm1)EPv spon-
taneous melanoma mouse model, in which melano-
cytes ectopically express the metabotropic glutamate 
receptor-1 (Grm1) under the control of the melanocyte- 
specific promoter dopachrome tautomerase.19 The same 
alteration has been observed in 40% of melanoma patient 
samples.20 The slow and continuous growth of melanoma 
lesions in these mice allows the investigation of immu-
nological alterations over prolonged time at different 
tumor stages. We previously reported that during tumor 
progression, MDSCs infiltrate the tumor tissue at a late 
tumor stage and that they exert immunosuppressive 
effects.21 In this study, we investigated the immunological 
changes at earlier tumor stages and observed that mela-
noma development within the dermis was accompanied 
by upregulation of molecules that can inhibit T cell func-
tion and by the concomitant loss of the CD11b+ dermal 
cDC2 population. Our results show that tumor growth 
could be delayed when checkpoint blockade antibodies 
against programmed cell death protein-1 (PD-1) and 
T- cell immunoglobulin and mucin- domain containing-3 
(TIM-3) were combined with a regimen that enhanced 
DC numbers and functionality, confirming the impor-
tance of DC for successful immunotherapy in melanoma.
MATERIALS AND METHODS
Mice
The tg(Grm1)EPv mice (kindly provided by Jürgen C. 
Becker, University of Duisburg- Essen) develop tumors 
predominantly in the ear and tail skin.19 21 Tg(Grm1)EPv 
mice were classified as tumor- free (TF) at the age of 6–10 
weeks, and compared with tumor- early (TE, 4–6 months 
of age) and tumor- advanced (TA, 8–10 months of age) 
mice (representative images of mice from all stages are 
shown in online supplemental figure S1A). Breeding 
pairs for C57BL/6N mice were purchased from Charles 
River in Germany. Langerin- EGFP mice (kindly provided 
by Bernard Malissen, CIML, Marseille22) were crossed 
to the tg(Grm1)EPv mice to generate the tg(Grm1)
EPv/langerin- EGFP mouse strain in which all Langerin+ 
DCs express EGFP. Pmel-1 mice with a transgene 
encoding for a CD8+ T cell receptor (TCR) recognizing 
the melanoma- associated antigen gp10023 were kindly 
provided by Thomas Tüting (Otto- von- Guericke Univer-
sity, Magdeburg). All mouse strains were housed and 
bred at the animal facility of the Department of Derma-
tology, Venereology and Allergology (Medical University 
of Innsbruck).
Mouse experimental manipulations
Intratumoral injections into ear tumors were performed 
under anesthesia in a final volume of 25 µL per ear. 
Anesthesia was induced with intraperitoneal adminis-
tration of a mix of PBS- Ketamine- Xylasol (ratio 1:1:2; 
aniMedica). Intraperitoneal injections were performed 
in a final volume of 100 µL. Ear thickness measurements 
for tumor growth monitoring in the tg(Grm1)EPv mice 
were conducted using a caliper (Kroeplin). A total of 
eight measurements per mouse were taken (four per 
ear) and from these the average ear thickness was calcu-
lated. Tumors in the tg(Grm1)EPv mouse model develop 
irregularly, and therefore, tumors of mice that are at the 
exact same stage can vary significantly. Thus, we displayed 
the ear thickness changes—Δear thickness—measured 
weekly. See online supplemental table 1 for reagents/
antibodies used for in vivo treatments. For the transplant-
able melanoma experiments, C57BL/6N and tg(Grm1)
EPv mice were injected subcutaneously into flank skin 
with 1.5×105 B16.OVA cells (kindly provided by Franca 
Ronchese, The Malaghan Institute of Medical Research, 
New Zealand) in PBS (Phospate buffered saline). Tumor 
growth was measured with a caliper and calculated by 
length×width.
Cell culture
For in vitro cell culture, we used RPMI medium (Lonza) 
supplemented with 10% heat- inactivated fetal calf serum 
(FCS, PAN- Biotech), 50 Units/mL penicillin/strep-
tomycin (Life Technologies) and 2 mM L- glutamine 
(Lonza).
Flow cytometry analyses of mouse skin, tumors and lymph 
nodes
Ear skin/tumors/LNs of tg(Grm1)EPv and C57BL/6N 
mice were processed as described previously.21 All 
staining steps for flow cytometry were performed for 
15 min at 4°C, unless stated otherwise. Non- specific 
Fc- receptor- mediated antibody binding was blocked with 
incubation for 15 min with anti- CD16/32 antibody (clone 
2.4G2, TONBO Biosciences). For exclusion of dead cells, 
samples were stained with eFluor-780 fixable viability dye 
(eBioscience), prior to any other staining step. Surface 
staining for CCR7 was performed for 30 min at 37°C. 
Restimulation of LN cell suspensions for intracellular 
cytokine staining was performed for 40 hours at 37°C with 
plate- bound anti- CD3 (5 µg/mL, clone 17A2, BD Biosci-
ences) and soluble anti- CD28 (1 µg/mL, clone 37.51, BD 
Biosciences). Tumor cell suspensions were restimulated 
with Dynabeads Mouse T- activator CD3/CD28 (Gibco) in 
a ratio of 1:1 beads:total cells, overnight at 37°C and were 
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supplemented with 30 Units/mL of recombinant mouse 
IL-2 (Peprotech). Cytokine release was blocked by addi-
tion of Brefeldin A (eBioscience) 4 hours prior to staining. 
For intracellular staining, the cells were fixed and perme-
abilized using the BD Biosciences Cytofix/Cytoperm Kit 
according to the manufacturer’s protocol. For FoxP3 
staining, the cells were fixed overnight and permeabi-
lized using the FoxP3 staining buffer kit according to the 
manufacturer’s protocol (eBioscience). For detection of 
gp100- specific CD8+ T cells we used the H- 2Db restricted 
KVPRNQDWL pentamer (Proimmune) according to the 
manufacturer’s protocol. All analyses were performed 
on a FACS Canto II (BD Biosciences) and CytoFLEX S 
(Beckman Coulter Life Sciences). See antibody list in 
online supplemental table 2.
Mass cytometry/CyTOF
Metal- labeled antibodies were obtained from Fluidigm or 
labeled in- house using the MaxPar X8 labeling kit (Flui-
digm) according to the manufacturer’s instructions.24 
Barcoding of samples was done with four different anti- 
CD45 metal conjugated antibodies (Y89 and palladium- 
labeled [Pd104, Pd106, and Pd108]). Immune cells were 
enriched using a density gradient of 40/90% Percoll (GE 
Healthcare). Staining was done as previously described.24 
In brief, Fc receptors were blocked using anti- CD16/
CD32 antibodies and cells were stained with 1 mL cisplatin 
(0.25 µM in PBS; Fluidigm) for 5 min at room tempera-
ture (RT) to exclude dead cells. Cells were stained 
with anti- CD45 barcoding antibodies for 30 min on ice. 
Samples were pooled for surface staining and incubated 
with the heavy metal conjugated antibody cocktail for 
20 min on ice. Cells were placed in 2% paraformaldehyde 
overnight at 4°C. The following day, cells were resus-
pended with permeabilization buffer (eBioscience/Invi-
trogen) for 30 min on ice and incubated at RT in 125 nM 
iridium intercalator (Fluidigm). Cells were washed with 
water, filtered, and acquired with the CyTOF2 (Fluidigm) 
at the Stanford Shared FACS Facility (Stanford Univer-
sity, USA). For CyTOF data analysis, FCS- formatted files 
were first normalized with Premessa (https:// github. 
com/ ParkerICI/ premessa/). Live, single cells, CD3- 
CD19- CD335- CD127- Ly6G- and CD45+ were gated using 
FlowJo. Events of interest were imported into CYT and 
transformed using arcsin (asinh x/5).
Isolation of CD8+ T cells, CFSE labeling and in vitro cocultures
CD8+ T cells were isolated from pmel-1 TCR transgenic 
mice recognizing the gp100 antigen.23 LNs and spleens 
underwent enzymatic digestion as described before.21 
CD8+ T cells were isolated using the mouse CD8a+ T cell 
isolation kit from Miltenyi according to the manufactur-
er’s instructions. For proliferation assays, isolated CD8+ T 
cells were labeled with 0.4 µM carboxyfluorescein succin-
imidyl ester (CFSE, Thermo Fisher Scientific) in PBS for 
3 min at RT. For isolation of migratory skin DC subsets, 
tumor- draining LNs of 7 tg(Grm1)EPv/Langerin- 
EGFP mice were isolated and enzymatically digested as 
described before.21 CD45+ cells were enriched with a 
1.119 g/mL density gradient according to the manufac-
turer’s protocol (Lymphoprep, Alere Technologies). 
Cell suspensions were then stained and sorted with a BD 
FACSAria II (BD Biosciences) (gating strategy described 
in online supplemental figure S4C). Equal numbers of the 
various DC subsets were cocultured in a ratio of 1:3 with T 
cells (3×105 DC:9×105 T cells) for 3 days in the presence of 
50 Units/mL recombinant mouse IL-2 (Peprotech).
CXCL9 and CXCL10 quantification in tumor lysates and blood 
serum
To determine the expression of the chemokines CXCL9 
and CXCL10, tumors were homogenized and resus-
pended in lysis buffer (BioRad Laboratories). Protein 
concentrations were determined by Bradford assay 
(BioRad Laboratories). All samples were diluted to a 
protein concentration of 5 mg/mL and CXCL9/CXCL10 
concentrations were analyzed by ELISA (R&D Systems, 
CXCL9 Cat#DY492 and CXCL10 Cat#DY466). Absor-
bance was measured with a Mithras LB 940 Multimode 
Microplate reader (Software MicroWin 2000), and 
concentrations were calculated as pg of cytokine per mg 
protein. Serum was analyzed without further dilution and 
CXCL9/CXCL10 levels were calculated as pg per mL 
serum.
RNA isolation
For RT- qPCR and for RNA- seq, RNA from mouse skin and 
tumors was isolated using TRIzol Reagent (Life Technol-
ogies) according to the manufacturer’s instructions. For 
microarray expression assays, RNA was isolated using the 
RNeasy Mini kit (Qiagen) according to the manufactur-
er’s instructions.
Real-time quantitative PCR
For RT- qPCR, genomic DNA was removed from total RNA 
with the RapidOut DNA removal kit (Thermo Fisher 
Scientific) and was reverse- transcribed into cDNA with 
random hexamers and SuperScriptR II Reverse Transcrip-
tase (Life Technologies) according to the kit’s instruc-
tions. qPCR analysis was performed on a BioRad CFX96 
using Brilliant III Ultra- Fast qPCR and RT- qPCR Master 
Mix (Agilent technologies). Sequences for probes and 
primers specific for mouse TATA- binding protein were 
selected by Primer Express software (Applied Biosystems) 
and synthesized by Microsynth. See online supplemental 
table 3 for the primers used.
RNA-sequencing analysis
Library preparations and RNA- seq was performed at the 
Medical University of Innsbruck Sequencing Core Facility 
according to the following procedure. Total RNA was 
extracted with Trizol (see above), quality validated with the 
Agilent Bioanalyzer and submitted to QuantSeq 3′ mRNA- Seq 
library preparation, following the manufacturer’s instruc-
tions (Lexogen). Resulting libraries were sequenced with 
the Ion Proton System (Thermo Fisher Scientific). The fastq 
reads were first processed though quality control pipeline 
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consisting of 3′ adapter removal with Cutadapt25 and quality 
trimming with Trimmomatic26 to remove bases with bad 
quality scores. All reads shorter than 22 nucleotides were 
removed. The quality trimmed reads were then mapped to 
the Mus musculus mm10 genome using a two- step alignment 
method; first alignment with STAR,27 followed by alignment 
of the unmapped reads using Bowtie 2.28 From the reads 
that mapped to multiple locations in the genome, only the 
primary alignment was retained. Reads that mapped to ribo-
somal RNA locations in the genome were removed from 
further analysis using the  split_ bam. py script from the quality 
control package RSeQC.29 HTSeq- count30 was used to count 
how many reads map to each gene in an annotation file. 
The DESeq231 R package was used to test for differential 
expression. The p values were adjusted for multiple testing 
based on the false discovery rate using the Benjamini–Hoch-
berg approach. Analysis and visualization of Gene Ontology 
terms associated with differentially expressed genes was 
performed using g:Profiler.32 Both groups of genes (up and 
downregulated, q value <0.1) were used as dual input for GO 
analysis. The biological terms are grouped together based 
on their shared genes where the similarity between terms is 
calculated using kappa statistics. The most significant term 
was chosen as a representative of the group (Benjamini–
Hochberg correction).
Microarray
Total RNA was isolated using the RNeasy Mini kit (Qiagen), 
according to the instructions of the manufacturer. The 
quality of the extracted RNA was evaluated by visualizing 
the ribosomal peaks on the Agilent Bioanalyzer 2100 and 
concentration was determined by the Nanodrop 8000. 
The samples were run on the Clariom S mouse arrays 
from Affymetrix/ThermoFisher utilizing the Affymetrix 
Whole Transcript Plus protocol which starts with 100 ng 
of total RNA as input. The final concentration of frag-
mented, biotin labeled ss- cDNA added to the hybridiza-
tion mix which went onto the array was 2.3 µg. The arrays 
were then hybridized at 45°C while rotating at 65 rpm for 
16 hours. The Clariom S mouse arrays were then washed 
and stained with the appropriate protocol for the Affy-
metrix Fluidics Station 450 and then was scanned on the 
Affymetrix GeneChip Scanner 3000 7G. The generated 
CEL files were analyzed in R using the oligo33 package 
and annotated using the annotation34 package with the 
clariomsmousetranscriptcluster35 database. Differential 
expression of probes was determined using the limma36 
package, and heatmaps were generated using superheat. 
Pathway analyses were conducted on the raw probe data 
using gene set enrichment analysis (GSEA).37
Statistical analysis
To determine whether parametric or non- parametric 
statistical tests should be used, all datasets from flow 
cytometry and RT- qPCR were tested for normality using 
the D’ Agostino- Pearson test. For up to two groups, statis-
tical significance was determined by two- tailed unpaired 
Student’s t- test (parametric) or Mann- Whitney test 
(non- parametric). For more than one group, statistical 
significance was determined with one- way analysis of vari-
ance (ANOVA) followed by Tukey’s multiple comparison 
test (parametric) or Kruskal- Wallis test followed by Dunn’s 
multiple comparison test (non- parametric). For repeated 
measurements within one experiment, Friedman test 
(non- parametric) or repeated measures one- way ANOVA 
(parametric) was used. A p value of <0.05 was considered 
statistically significant (*), <0.01 very significant (**), 
<0.001 highly significant (***) and <0.0001 extremely 
significant (****). Error bars represent SE of the mean. 
All statistical analyses and graphics were performed using 
Graphpad Prism V.8.0.
RESULTS
Immunosuppressive molecules increase with tumor 
progression
Our earlier work demonstrated that late stage tumors 
of the tg(Grm1)EPv mice were infiltrated by MDSCs 
and that these could suppress melanoma- specific T cell 
responses.21 In this study, we aimed at identifying mech-
anisms of immune evasion that occur earlier in tumor 
development. For this, we performed RNA- seq of ear 
skin from tumor- free (TF), tumor- early (TE) and tumor- 
advanced (TA) tg(Grm1)EPv mice (see online supple-
mental figure S1A for the different stages). Our RNA- seq 
analysis of progressing tumors revealed an upregulation 
of immunosuppressive molecules that can inhibit T cell 
function (figure 1A). By RT- qPCR we confirmed that the 
mRNA levels for PD- L1 and Galectin-9, the ligands for the 
inhibitory molecules PD-1 and TIM-3 respectively, were 
strongly upregulated in advanced tumors (figure 1B). By 
flow cytometry we detected PD- L1 expression on multiple 
cell types, including DCs, CD4+ and CD8+ T cells (online 
supplemental figure S1B,C). Viable melanoma cells 
cannot be retrieved after enzymatic digestion in this 
mouse model, therefore we could not determine the 
expression of PD- L1 and/or galectin-9 on the surface of 
tumor cells. Whereas the percentages of tumor- infiltrating 
CD4+ and CD8+ T cells only slightly changed with tumor 
progression (online supplemental figure S1D,E), most of 
the T cells expressed either one of the inhibitory recep-
tors PD-1 and TIM-3 or both (figure 1C). The few regula-
tory T cells (Tregs) in the tumors mainly expressed TIM-3 
(online supplemental figure S1F,G).
To examine whether T cells become functionally impaired 
with tumor progression, we evaluated their cytokine produc-
tion after in vitro restimulation with antibodies against CD3 
and CD28. A gradual decrease in the percentages of IFNγ 
and TNFα producing T cells was observed; however, this 
decrease was statistically significant only for the fraction of 
CD4+ T cells producing both IFNγ and TNFα and not for 
the rest of the populations (figure 1D). Furthermore, T cells 
from tumor- draining LNs produced IFNγ and TNFα even 
during tumor progression (figure 1E). These results suggest 
that tumor- infiltrating T cells (TILs) are able to produce 
cytokines; however, they become functionally impaired due 
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Figure 1 Immunosuppressive molecules increase with tumor progression. (A) RNA- seq analysis was performed with ear 
skin/tumor tissue from TF (tumor- free), tumor- early (TE) and TA (tumor- advanced) tg(Grm1)EPv mice. The heatmap depicts 
normalized and relative expression (z- score) levels of several checkpoint ligands. Mean expression for three mice per group 
is shown. (B) The mRNA levels of programmed death ligand-1 (PD- L1) and Galectin-9 from ear skin/tumors of TF, TE, TA mice 
were quantified by real- time quantitative PCR. Fold change in comparison to the TF stage is shown for five to six mice per 
group from one to two independent experiments. (C) Percentages of PD-1+ and TIM-3+ conventional CD4+ and CD8+ T cells 
from ear skin/tumors of TF, TE, TA tg(Grm1)EPv mice were determined by flow cytometry. Summary graph for seven mice per 
group from four independent experiments is shown. (D, E) Cell suspensions from ear skin/tumors (D) and draining lymph nodes 
(LNs) (E) were restimulated in vitro with anti- CD3/anti- CD28 mAbs. The percentages of interferon γ (IFNγ) and tumor necrosis 
factor α (TNFα) producing CD4+ and CD8+ T cells were analyzed by flow cytometry. Results are from three independent 
experiments with six to eight mice per group. (F) Tg(Grm1)EPv mice at the transition from TE to TA stage (6.5–7 months old) 
were treated intraperitoneally with anti- PD- L1 mAb twice per week. Tumor growth was determined by measuring ear thickness 
changes over time. Results for six mice per group from two independent experiments are shown. Statistical significance was 
determined using one- way analysis of variance or Kruskal- Wallis analysis (B–E) and two- tailed unpaired Student’s t- test (F). 
Graphs show the mean ± SE. *p<0.05; **p<0.01; ***p<0.001.
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to the presence of immunosuppressive molecules, such as 
PD- L1. Thus, we treated tg(Grm1)EPv mice at the transi-
tion between the TE and the TA stages with a mAb against 
PD- L1 but this treatment was not sufficient to delay tumor 
growth (figure 1F). In agreement with a previous study,7 this 
therapy also failed to induce infiltration of CD4+ and CD8+ 
T cells into the tumor (online supplemental figure S1H).
We conclude that the tg(Grm1)EPv melanoma mouse 
model does not respond to monotherapy with PD- L1 
blockade and that additional mechanisms limit the anti-
tumor immune response in these tumors.
DCs gradually decrease in melanoma lesions and can be 
restored by a DC boost approach
A significant decrease in intratumoral DCs has been 
observed in primary human melanoma lesions and this 
has been associated with a worse prognosis.7 10 38 To 
examine whether this holds true for the tg(Grm1)EPv 
mice, we analyzed the changes in the percentages and 
numbers of the different skin DC subsets during tumor 
progression. The cDC2 population showed a gradual 
decrease with tumor growth, whereas LC and cDC1 
numbers remained unchanged (figure 2A, gating strategy 
shown in online supplemental figure S2A). As DCs are 
crucial in the induction of antitumor immune responses, 
we investigated whether we could overcome this DC 
loss. The decrease in dermal cDC2 was pronounced at 
the transition between the TE and the TA stage (6.5–7 
months old), so we examined whether DC numbers in 
the tumor microenvironment (TME) could be restored 
during that period. Indeed, systemic administration of 
Flt3L for 1 week increased the frequencies of dermal 
cDC2 in the tumor (online supplemental figure S2B). 
To ensure proper maturation of the recruited DCs, we 
performed intratumoral injections with the toll- like 
receptor (TLR)-3 ligand polyI:C and a mAb against 
CD40 (the treatment with Flt3L and polyI:C/anti- CD40 
will be referred to as DC boost therapy from now on, 
treatment scheme shown in online supplemental figure 
S2C). We performed CyTOF analysis of the tumors to 
accurately identify the different myeloid populations.39 
Samples from both the DC boost and the isotype group 
were concatenated and a viSNE analysis was performed. 
Through manual gating (gating strategy shown in online 
supplemental figure S2D) the major myeloid populations 
were identified and overlayed on the viSNE map shown 
in figure 2B. The viSNE plots highlight in blue the most 
dominant myeloid cell types present in control and DC 
boost treated mice (figure 2B). The analysis revealed 
higher percentages of cDC1s, cDC2s and monocytes by 
the DC boost regimen, whereas LCs remained mostly 
unchanged (figure 2C and online supplemental figure 
S2E). These cDC1s and cDC2s had increased expression 
of CD86, MHC- II and CCR7, suggesting that these cells 
were highly activated and developed migratory potential 
towards the tumor- draining LN (figure 2D,E).
Thus, in addition to the upregulation of immunosup-
pressive molecules within the TME, the loss of dermal 
cDC2 points at impaired antitumor immunity. A DC boost 
therapy with Flt3L plus polyI:C/anti- CD40 restores the 
pool of intratumoral DCs with an activated phenotype.
Boosting DC numbers and function facilitates responsiveness 
to checkpoint blockade
Our data so far identified two potential mechanisms 
that could hamper antitumor immune responses in the 
tg(Grm1)EPv mouse model: the upregulation of mole-
cules that can inhibit T cell function in the tumor and 
the decrease of intratumoral DCs. As monotherapy with 
anti- PD- L1 mAb was not sufficient to delay tumor growth, 
we sought to boost DC function and at the same time 
block inhibitory molecules on T cells. For this, we treated 
tg(Grm1)EPv mice with a DC boost therapy consisting of 
Flt3L daily for 1 week and weekly intratumoral injections 
with polyI:C/anti- CD40 for 5 weeks. As intratumoral T 
cells of the tg(Grm1)EPv mice expressed both PD-1 and 
TIM-3 (figure 1C), we also tested checkpoint blockade 
therapy by administering blocking mAbs for both mole-
cules twice a week for weeks 2–5. An additional group 
that received both treatments (combination) was also 
included (treatment scheme in figure 3A). Although DC 
boost and checkpoint blockade single therapies delayed 
tumor growth, only the combination treatment inhibited 
tumor growth significantly in comparison to the isotype 
control group (figure 3B,C).
These results indicate that the combination of check-
point blockade with an approach that restores the pool of 
activated DC can control tumor growth.
The DC boost results in increased infiltration of activated DCs 
and T cells into tumors
To understand the immunological processes mediating 
the delay in tumor growth in the tg(Grm1)EPv mouse 
model, we examined the changes in the immune cell 
composition of the tumors after 5 weeks of treatment. First 
of all, the DC boost approach led to a statistically signif-
icant increase of the total CD45+ immune cells that was 
persistent in the combination group (figure 4A). When 
we looked into detail, we detected more intratumoral 
cDC1 and cDC2 (figure 4B) that expressed high levels of 
CD40 (figure 4C). Apart from the increased frequencies 
of DCs, we observed a recruitment of CD4+ and CD8+ 
T cells (figure 4D) as well as CD4+ Tregs and MDSCs in 
the tumors (online supplemental figure S3A,B). Never-
theless, the delay in tumor growth by the combination 
treatment (figure 3B,C) suggests that antitumor immu-
nity overrules immunosuppression. Indeed, the increased 
ratio of CD4+ T cells/Tregs in the same groups indicates a 
dominance of T helper cells over regulatory, immunosup-
pressive cells (online supplemental figure S3C). This was 
not reflected in the ratio of CD8+ T cells/Tregs (online 
supplemental figure S3D). Along with the intratumoral 
CD8+ T cells, we detected increased frequencies of gp100- 
specific CD8+ T cells in the tumors of mice that received 
the DC boost treatment, suggesting the induction of a 
tumor- specific immune response (figure 4E). Previous 
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Figure 2 Dendritic cells (DCs) gradually decrease in melanoma lesions and can be restored by a DC boost approach. (A) Ear 
skin/tumors of TF (tumor- free), tumor- early (TE) and tumor- advanced (TA) tg(Grm1)EPv mice were analyzed by flow cytometry 
for the percentages of skin DC subsets (gating strategy shown in online supplemental figure S2A). Results from six to eight to 
8 mice per group from five independent experiments are shown. (B) tg(Grm1)EPv mice at the transition from TE to TA stage 
(6.5–7 months old) were treated as illustrated in online supplemental figure S2C. Changes in the myeloid cells were determined 
by mass cytometry. Top panel: the different populations shown in the viSNE map were identified by manual gating (online 
supplemental figure S2D). Bottom panels: In blue, the distribution of the identified cells for isotype control (left) and DC boost 
(right) treated mice are shown. (C) The frequencies of the different skin DC subsets in isotype and DC boost treated mice 
were determined. (D) The frequencies of activated cDC1 and cDC2 as determined by CD86 expression are shown. (E) Surface 
expression of XCR1, CD24, MHC- II, CD86, CD11b, Sirpα, CCR7, CD64, CX3CR1 and Ly6C by the various myeloid subsets 
are shown on the viSNE plots. For (B)–(E) results for three mice from two independent measurements are shown. Statistical 
significance was determined using one- way analysis of variance or Kruskal- Wallis analysis (A) and two- tailed unpaired Student’s 
t- test (C and D). Graphs show the mean ± SE. *p<0.05; **p<0.01; ***p<0.001.
P
rotected by copyright.


















8 Prokopi A, et al. J Immunother Cancer 2021;9:e000832. doi:10.1136/jitc-2020-000832
Open access 
studies have shown that infiltrating DCs produce chemo-
kines crucial for the recruitment of T cells.6 40 RT- qPCR 
analysis for Cxcl9 and Cxcl10 showed that the DC boost 
approach upregulated both chemokines and this was 
even more pronounced in the combination treatment 
group (figure 4F). We observed a similar trend for the 
protein levels of these chemokines in the tumor tissue 
(online supplemental figure S3E). Microarray analysis 
of the tumors for additional chemokines required for T 
cell recruitment into tissues showed that their expression 
was also increased in the combination treatment group 
(figure 4G).
Altogether, our data outline that the DC boost approach 
is essential to recruit activated DCs and T cells to the 
tumors to mediate anti- tumor immunity.
DC boost treatment improves antitumor immune responses in 
the draining lymph node
Our results so far show that the DC boost approach 
modulates the immune infiltrate in tumors in favor of 
activated DC and T cells. Moreover, Gene Set Enrich-
ment Analysis (GSEA) performed on the microarray 
data showed that tumors treated with the combination 
approach, were enriched for pathways related to antigen 
processing and (cross-) presentation (online supple-
mental figure S4A,B). As the tumor- draining LN is the 
location where de novo T cell responses are initiated, we 
next investigated the immunological changes there. We 
found that after 5 weeks of treatment the migratory cDC2 
increased in frequencies whereas the cDC1 subset and 
LCs were unchanged (figure 5A, gating strategy in online 
Figure 3 Boosting dendritic cell (DC) numbers and function facilitates responsiveness to checkpoint blockade. (A) The 
treatment scheme for isotype control, DC boost, checkpoint blockade and combination therapies over 5 weeks is depicted. DC 
boost consisted of daily injections of 10 µg Fms- related tyrosine 3 ligand (Flt3L) intraperitoneally (i.p.) during the first week of 
treatment and weekly intratumoral injections of polyI:C and anti- CD40 (25 µg each per mouse). Checkpoint blockade consisted 
of i.p. injections of 100 µg/mouse of both anti- PD-1 and anti- TIM-3 blocking mAbs and was administered twice per week 
starting from the second week. Blue arrows indicate DC boost interventions and red arrows indicate checkpoint blockade. Mice 
in the combination group received treatment with DC boost and checkpoint blockade. Isotype control therapy consisted of PBS 
instead of Flt3L and polyI:C and isotype control antibodies for anti- CD40, anti- PD-1/anti- TIM-3. (B) Tg(Grm1)EPv mice at the 
transition from tumor- early (TE) to tumor- advanced (TA) stage were treated and ear thickness changes for 8–10 mice per group 
from two independent experiments were measured weekly. *p<0.05. (C) Ear thickness measured at weeks 4 and 5 is shown. 
Statistical significance was determined using the Kruskal- Wallis analysis for (B) and (C). PD-1, programmed cell death protein-1; 
TIM-3, T- cell immunoglobulin and mucin- domain containing-3.
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Figure 4 The DC boost results in increased infiltration of activated dendritic cells (DCs) and T cells into tumors. Tg(Grm1)EPv 
mice at the transition from tumor- early (TE) to tumor- advanced (TA) stage were treated for 5 weeks as described in figure 3A. 
(A–E) Frequencies of the CD45+ immune cells (A), skin DC subsets (B), CD40 expression on DC subsets (C), CD4+ and CD8+ 
tumor- infiltrating T cells (D) and gp100- specific CD8+ T cells (E) were determined by flow cytometry. For (A)–(E), n=8–10 
mice per group from two independent experiments. (F) The mRNA levels for Cxcl9 and Cxcl10 were quantified by real- time 
quantitative PCR. Fold change in comparison to the isotype control is shown for n=4–6 mice per group from three independent 
experiments. (G) Tumor RNA from isotype control and combination therapy treated mice was analyzed by microarray. Heatmap 
from microarray data displaying the normalized and relative expression (z- score) of genes associated with lymphocyte 
trafficking. n=6 mice per group from two independent experiments. For (A)–(F), statistical significance was determined 
using one- way analysis of variance or Kruskal- Wallis analysis. Graphs show the mean ± SE. *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. PD-1, programmed cell death protein-1; TIM-3, T- cell immunoglobulin and mucin- domain containing-3.
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Figure 5 DC boost treatment improves antitumor immune responses in the draining lymph node. (A) Tg(Grm1)EPv mice at the 
transition from tumor- early (TE) to tumor- advanced (TA) stage were treated for 5 weeks as described in figure 3A. Percentages 
of migratory skin dendritic cell (DC) subsets were determined by flow cytometry in the tumor draining lymph nodes (LNs). 
(B–G) Tg(Grm1)EPv/Langerin- EGFP mice at the transition from TE to TA stage were treated with the DC boost regimen as in 
online supplemental figure S2C. The three main migratory skin DC subsets (LCs, cDC1, cDC2) were sorted from the tumor- 
draining LNs (see online supplemental figure S4C for sorting strategy). Sorted DCs were cocultured with gp100- specific CD8+ 
T cells isolated from pmel-1 mice in a ratio of DCs:T cells 1:3 for 3 days. As a negative control, T cells were cultured without 
stimulation but with IL-2 only (+IL-2). T cells cocultured with gp100 peptide loaded DCs served as positive control (Pos ctrl). (B) 
Representative histograms showing carboxyfluorescein succinimidyl ester (CFSE) dilution of CD8+ T cells in response to the 
different DC subsets. (C) Percentages of proliferated CD8+ T cells from three independent experiments. (D) Representative dot 
plots showing the expression of PD-1 and TIM-3 on the CD8+ T cells after 3 days of coculture with the different DC subsets. 
(E) Percentages of PD-1+ and TIM-3+ CD8+ T cells from three experiments. (F) At day 3 of coculture, CD8+ T cells were 
restimulated with anti- CD3/anti- CD28 mAbs and production of IFNγ and TNFα was measured by intracellular flow cytometry. 
Representative dot plots showing cytokine production by T cells in response to the different DC subsets. (G) Percentages 
of IFNγ+ and of TNFα+ CD8+ T cells from three experiments are shown. (H and I) LN cell suspensions of Tg(Grm1)EPv mice 
at the transition from TE to TA stage that were treated for 5 weeks as described in figure 3A were restimulated in vitro with 
anti- CD3/anti- CD28 mAbs. Percentages of IFNγ+ and TNFα+ CD4+ T cells (H) and CD8+ T cells (I) were analyzed by flow 
cytometry. Statistical significance was determined using one- way analysis of variance (ANOVA) or Kruskal- Wallis analysis (A, 
H, I), Friedman test (C and E) and repeated- measures one- way ANOVA (G). Graphs show the mean ± SE. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. IFNγ, interferon γ; PD-1, programmed cell death protein-1; TIM-3, T- cell immunoglobulin and mucin- 
domain containing-3; TNFα, tumor necrosis factor α.
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supplemental figure S4C). We observed a similar pattern 
at earlier time points following the DC boost approach 
(online supplemental figure S4D,E). Previous studies 
reported that within tumors, the main DC subset involved 
in the cross- presentation of tumor antigens is the cDC1.6 7 
However, the priming ability of the various migratory skin 
DCs in the tumor- draining LNs is still incompletely 
understood, so we aimed to investigate the cross- priming 
abilities of the different migratory DC subsets in the 
tumor- draining LNs after DC boost treatment. Tg(Grm1)
EPv/langerin- EGFP mice that allow cell sorting of 
Langerin+ DC/LC were used at the transition from TE 
to TA and treated with the DC boost regimen for 1 week 
(see scheme in online supplemental figure S2C). One 
day after the end of the treatment, we sorted the three 
main migratory DC subsets from the tumor- draining LNs 
(see online supplemental figure S4C for sorting strategy) 
and tested them for their ability to cross- present tumor- 
derived antigen to gp100- specific TCR- transgenic CD8+ 
T cells.23 The in vitro T cell proliferation confirmed that 
cDC1 cross- present tumor antigens and induce prolif-
eration of gp100- specific CD8+ T cells. In addition, we 
observed that the DC boost approach reinforced migra-
tory skin cDC2 to perform this task (figure 5B,C). Further-
more, the cDC2 induced coexpression of PD-1 and TIM-3 
on CD8+ T cells, making them susceptible to checkpoint 
blockade therapy (figure 5D,E). When we restimulated 
CD8+ T cells from these cocultures with anti- CD3/anti- 
CD28, we found that IFNγ and TNFα production was 
induced by all three migratory DC subsets, with migratory 
cDC1 and cDC2 being the most potent in the induction 
of the double- producers (figure 5F,G). By examining the 
functional properties of T cells in the tumor- draining 
LNs in mice that had received treatments for 5 weeks, 
we detected higher numbers of IFNγ and TNFα-pro-
ducing CD4+ and CD8+ T cells after in vitro restimulation 
(figure 5H,I).
These observations reveal that even after 5 weeks of 
treatment, there is continuous migration of dermal DCs 
to the tumor- draining LNs, with this effect being more 
pronounced for the cDC2 subset. The DC boost approach 
enables all skin DC subsets to cross- present endogenous 
gp100 tumor- associated antigen to CD8+ T cells leading 
to their activation. Furthermore, it enhances the in vivo 
function of CD4+ and CD8+ T cells in the tumor- draining 
LN, an important location for T cell priming.
Combination of DC boost with checkpoint blockade of PD-1 
and TIM-3 results in a higher cytotoxic activity in the tumor
To understand better the immunological processes in the 
treated tumors, we analyzed the tumor- infiltrating CD4+ 
and CD8+ T cells. Both subsets contained more PD-1 
and TIM-3 positive cells when compared with the isotype 
control group, an effect that was most significant in the DC 
boost and combination groups (figure 6A,B). Thus, the 
DC boost approach induced these surface molecules, and 
especially of PD-1, which in turn rendered T cells more 
responsive to checkpoint blockade. A detailed analysis 
of genes important for T cell function was performed 
with microarray and RT- qPCR. Several genes related to 
immune cell- related cytotoxicity, for example, Gzmb, Fasl, 
Prf1 and activation of T cells, for example, Il2, Ifng, Tnf, 
were upregulated in tumors that received the combina-
tion therapy (figure 6C). RT- qPCR analysis revealed that 
in the DC boost group, the mRNA expression of Ifn, Gzmb 
and Tnf was increased (figure 6D). But in fact, the combi-
nation therapy with checkpoint blockade therapy was 
essential to achieve maximal expression of these mole-
cules (figure 6D). To investigate if the T cells are able to 
mediate antitumor immunity, we injected transplantable 
B16.OVA melanoma cells at week 4 of treatment into the 
flank skin of tg(Grm1)EPv mice and terminated treat-
ment at week five according to the original treatment 
scheme (figure 3A). Growth of B16 tumors was delayed 
in non- treated tg(Grm1)EPv mice due to a pre- existing 
antitumor immune response when compared with naive 
C57BL/6 mice (online supplemental figure S5A). Still, 
B16 tumors eventually grew and prolonged survival 
could be achieved only in mice that received either the 
DC boost or the combination treatment (online supple-
mental figure S5B). Finally, we wanted to translate this 
into the transgenic melanoma model and investigated 
the survival of tg(Grm1)EPv with spontaneous tumors 
after therapy cessation and we observed that the combi-
nation treatment prolonged survival (figure 6E).
These results demonstrate that the DC boost approach 
drives alterations in the TME that increase the immuno-
genicity of tumors and renders them more responsive to 
immunotherapy with checkpoint inhibitors. On addition 
of anti- PD-1 and anti- TIM-3 to the DC boost treatment, 
the cytotoxic capacity of the T cells is released leading to 
efficient tumor growth control.
DISCUSSION
The current research focus in clinical tumor immunology 
is mainly centered on TILs and how their function can 
be restored with checkpoint blockade.2 3 Recently, the 
importance of DCs for this type of immunotherapy was 
revealed,5 and several reports demonstrated a dominant 
role for cDC1 in the cross- presentation of tumor antigens 
in the tumor microenvironment (TME).6–8 Nevertheless, 
the role of the migratory skin DC in priming melanoma- 
specific T cell responses in the tumor- draining LNs is just 
partly understood. In our study, we used the tg(Grm1)
EPv spontaneous melanoma mouse model which allows 
for the in- depth assessment of coevolution of the tumor- 
immune microenvironment, due to slow and gradual 
melanoma growth.19 21 Characterization of the TME 
demonstrated an upregulation of T cell inhibitory mole-
cules during tumor progression with a concomitant loss 
of cDC2 that might facilitate tumor immune evasion. 
Indeed, we report here that boosting the numbers and 
activation of intratumoral cDC1 and cDC2 is key for the 
success of immunotherapy with checkpoint blockade. 
Moreover, the DC boost approach equips not only the 
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Figure 6 Combination of DC boost with checkpoint blockade of programmed cell death protein-1 (PD-1) and T- cell 
immunoglobulin and mucin- domain containing-3 (TIM-3) results in a higher cytotoxic activity in the tumor. Tg(Grm1)EPv 
mice at the transition from tumor- early (TE) to tumor- advanced (TA) stage were treated for 5 weeks as described in figure 3A. 
Representative contour plots and summary graphs depicting PD-1 and TIM-3 expression of CD4+ (A) and CD8+ (B) T cells from 
tumors of mice from different treatment groups. n=8–10 mice per group from two independent experiments. (C) Tumor RNA 
from isotype control and combination therapy treated mice was analyzed by microarray. The heatmap depicts the normalized 
and relative expression (z- score) of genes associated with immune- mediated cytotoxicity for six mice per group from two 
experiments. (D) The mRNA levels for Ifng, Tnf and GzmB were quantified by real- time quantitative PCR. Fold change in 
comparison to the isotype control is shown for four to six mice per group from three independent experiments. (E) Long- term 
survival of tg(Grm1)EPv mice after cessation of treatment at week five in isotype control and combination treatment groups 
(treatment scheme in figure 3A). Six mice per group from one experiment are shown. Statistical significance was determined 
with one- way analysis of variance or Kruskal- Wallis analysis (A, B and D) or log- rank (Mantel- Cox) test (E). Graphs in (A), (B) and 
(D) show the mean±SE. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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migratory cDC1 but also the migratory cDC2 in the 
tumor- draining LNs of the tg(Grm1)EPv mouse model 
with the ability to prime gp100- specific CD8+ T cells. 
In the end, we demonstrate that a combination therapy 
with DC boosting reagents and checkpoint blockade anti-
bodies restored T cell responses, delayed tumor growth 
and prolonged survival of tumor- bearing mice.
We have previously shown that MDSCs are recruited 
to advanced melanoma lesions of the tg(Grm1)EPv mice 
and that these MDSCs are able to inhibit gp100- specific 
CD8+ T cell responses.21 In the present study, we exam-
ined how antitumor immune responses are impaired at 
the interface between early and advanced tumor stages. 
One major mechanism identified was the upregulation of 
PD- L1 and galectin-9 in the tumor. As monotherapy with 
anti- PD- L1 was not sufficient to control tumor growth, we 
examined further changes that may occur in the tumor- 
immune microenvironment. A decrease in skin DCs has 
already been described in earlier studies that charac-
terized the immune infiltrate in primary human mela-
noma lesions.7 10 In line with this, tumor progression in 
the tg(Grm1)EPv mice is accompanied by a continuous 
loss of dermal cDC2, the most abundant DCs within the 
growing melanoma lesions. As DCs are key mediators of 
antitumor immune responses,6–8 10 we sought to increase 
their numbers and activation. For this, we used treatment 
with Flt3L which has been described to expand all DC 
subsets except LCs in lymphoid organs and peripheral 
tissues, including tumors.7 18 Furthermore, we used an 
adjuvant mix consisting of polyI:C and a mAb against 
CD40, as previous studies reported that activating DCs in 
tumors is essential for efficient and long- lasting immune 
responses.41 We report here that this DC boost approach 
(Flt3L plus polyI:C/anti- CD40) enhanced the numbers 
and activation of intratumoral dermal cDC1 and cDC2.
A necessary step in the induction of antitumor immune 
responses is the priming of T cells in the tumor- draining 
LN. The capacity of migratory cDC1 and cDC2 to cross- 
present antigen has been observed before in the steady 
state.42 However, it is not entirely understood what 
exactly is the role of the migratory skin DC subsets in the 
priming of melanoma- specific T cells and how this role 
changes in response to immunotherapy. In our study, we 
observed higher frequencies of migratory cDC2 in the 
tumor- draining LNs after DC boost treatment. Through 
co- cultures of sorted migratory skin DC subsets with 
gp100- specific CD8+ T cells after DC boost treatment, 
we observed that both migratory dermal DC, cDC1 and 
cDC2, and to a lesser extent LCs, can cross- present gp100 
tumor- associated antigen. Thus, the DC boost approach 
can enhance the cross- presenting capacity of all skin DC 
subsets in the tumor- draining LN, an essential step in the 
priming process of antitumor immunity.
In line with this, the DC boost approach is able to 
partially control tumor growth in the tg(Grm1)EPv 
mouse model. More specifically, we observed recruit-
ment of CD4+ and CD8+ T cells into treated tumors that 
expressed to a high extent PD-1 and/or TIM-3, rendering 
them susceptible to subsequent checkpoint blockade 
therapy. Thus, we designed a combination therapy 
consisting of the DC boost and checkpoint blockade anti-
bodies against PD-1 and TIM-3. Indeed, this combination 
treatment significantly delayed tumor growth. The reason 
for better efficacy was the strong induction of cytokines 
and cytotoxic molecules, including granzyme B, IFNγ and 
TNFα in the treated tumors. In line with this, mice treated 
with combination therapy were partly protected against a 
subsequent challenge with transplantable B16.OVA mela-
noma cells indicating the induction of melanoma- specific 
T cells. Indeed, we detected infiltration of gp100- specific 
CD8+ T cells into the tg(Grm1)EPv- treated tumors. More-
over, we demonstrated prolonged survival of tg(Grm1)
EPV mice even after cessation of therapy suggesting long- 
term control of spontaneous tumors.
A recent study demonstrated that cDC2 are crucial 
for the initiation of CD4+ T cell- driven anti- melanoma 
responses and they correlate with a better response to 
anti- PD-1 therapy; Treg abundance in steady state tumors 
is a factor limiting the ability of cDC2 to initiate CD4+ 
T cell responses.43 Our results show that the DC boost 
approach enhances not only the numbers and activation 
of intratumoral DC and T cells but also the frequencies of 
intratumoral Tregs. Our results however indicate a domi-
nance of conventional CD4+ T cells over CD4+ Tregs. 
Along with the increase in Tregs, we observed an increase 
in the frequencies of MDSCs. Previous studies have shown 
that treatment with polyI:C and/or anti- CD40 can limit 
the suppressive capacity of these cells.44 45 It is there-
fore likely that the DC boost treatment used here limits 
MDSC- mediated immunosuppression. Nevertheless, 
future studies should address the exact mechanisms that 
mediate the protection of conventional CD4+ and CD8+ 
T cells from immunosuppression mediated by Tregs and 
MDSCs, as this will provide insight on how specific thera-
pies can limit immunosuppression and enhance respon-
siveness to checkpoint blockade therapy.
Our study, which employed the tg(Grm1)EPv sponta-
neous melanoma mouse model, provides strong evidence 
that enhancing DC numbers and activation can improve 
the recruitment of intratumoral T cells by upregulation 
of chemokines required for the recruitment of T cells, 
including the type I IFN- inducible CXCL9 and 10 chemo-
kines.46 As checkpoint blockade alone did not mediate 
these effects, the DC boost approach appears to be key 
in this process. Still, for full T cell function in regard to 
cytokines and cytotoxicity the addition of checkpoint 
blockade therapy was required. Thus, we conclude that 
DCs are essential for efficient checkpoint blockade 
therapy by equipping T cells with cytotoxic properties. 
Further studies with additional melanoma mouse models 
where tumor growth is driven by different mutations 
such as the BrafV600E- Pten-/- model,47 along with the use of 
mouse models that allow for the ablation of specific DC 
subsets should evaluate the potential of the different DC 
subsets in both tumors and tumor- draining LNs in driving 
T cell responses during immunotherapy.
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CONCLUSIONS
Our data demonstrate that DCs are crucial determinants 
of tumor immunogenicity; upon DC boost treatment, 
there is an infiltrate of activated DCs and CD4+ and CD8+ 
T cells in the tumors, whereas the migratory skin DCs, 
and especially the dermal cDC1 and cDC2, acquire the 
ability to prime CD8+ T cell responses in the tumor- 
draining LN. Therefore, therapies to enhance respon-
siveness to checkpoint blockade may well benefit from 
a component that boosts the numbers and function of 
DCs. Administration of recombinant Flt3L was shown to 
be effective in the expansion of DCs and safe for healthy 
volunteers,48 increase the frequencies of peritumoral DCs 
in metastatic colon cancer patients49 and restore respon-
siveness to anti- PD-1 therapy in patients with lymphoma 
when combined with radiotherapy and administration of 
polyI:C.50 Ongoing clinical trials will reveal whether Flt3L 
in combination with other immunostimulatory agents 
including TLR ligands and anti- CD40 can induce durable 
clinical responses and prolong survival in patients with 
melanoma .
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